Xospata

Showing 3 posts of 3 posts found.

NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia

January 23, 2020
Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia

The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …

European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia

October 28, 2019
Sales and Marketing Astellas, Xospata, leukaemia, pharma

Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …

Astellas’ Xospata becomes US-approved drug for FLT3-mutated acute myeloid leukaemia

November 29, 2018
Sales and Marketing Astellas, FDA, US, Xospata, acute myeloid leukamia

Astellas has revealed that Xospata (gilteritinib) has been awarded FDA approval as a treatment for relapsed or refractory acute myeloid …

Latest content